GOALS & ACHIEVEMENTS
Sits firmly at the intersection of health, technology, and execution.
Blake Marggraff is a scientist and entrepreneur, currently serving as Chief Executive Officer of Epharmix, a health IT company creating the first portfolio of clinically proven digital interventions. Epharmix investors and advisors include Peter Diamandis, founder of XPRIZE and Singularity University, and Randy Haykin, founding officer of Yahoo!, Inc. Epharmix leverages clinical trials to validate each disease-specific product (from EpxDiabetes to EpxCongestiveHeartFailure), bringing the gold standard of medical research to efficient, scalable technology. Epharmix has demonstrated meaning clinical outcomes for several major chronic conditions and has received recognition including the WUSTL Global Impact Award in 2016. Prior to founding Epharmix, Blake co-founded the education technology company Betabox Labs, scaling to dozens of universities across the U.S.
Blake sits firmly at the intersection of health, technology, and execution. His passion for both technology and research originated during his work in nuclear medicine, one part of which was awarded the Gordon E. Moore Award, the top price of the Intel International Science and Engineering Fair in 2011, for simulation of novel, inexpensive, and effective cancer treatment and low-tech eukaryotic cell death quantification. Blake's background in research, commercialization, and fundraising have led Blake to give dozens of presentations on to thousands of STEM students across the country.
Prior to graduating from Washington University in St. Louis in May, 2015, Blake balanced academics with rigorous extracurricular work: founding two companies, attending pitch and business plan competitions across the country, and leading the development of new biomedical devices. Blake is a member of the 2015 St. Louis "30 Under 30" class, 2014 Arch Grant winner (of >600 companies from around the world), St. Louis "top 35 innovator," and Inc. Magazine "Coolest College Startup" founder.Back To Ambassadors
Our newsletter is on a brief hiatus, but please do subscribe so you’ll be on our list when we return.